度拉糖肽治疗患者HbA1c降低与糖尿病病程、微血管疾病及BMI无关:REWIND试验事后分析
本文为REWIND试验的事后分析,评估度拉糖肽1.5 mg治疗者长期HbA1c变化。结果显示,72个月治疗期间度拉糖肽组HbA1c较安慰剂组显著降低(最小二乘均值差=-0.61%,P<0.001),且不受糖尿病病程、既往微血管疾病及BMI影响。
要点
- 度拉糖肽1.5 mg组72个月内HbA1c较安慰剂组降低,最小二乘均值差=-0.61%(P<0.001)。
- HbA1c降低不受糖尿病病程、既往微血管疾病及BMI影响(交互作用P均>0.07)。
- 0-12个月度拉糖肽组HbA1c下降速率高于安慰剂组,12-72个月上升速率亦较高,校正后无统计学意义。
核心结论
- 度拉糖肽1.5 mg治疗与72个月内HbA1c持续降低相关,且不受基线糖尿病病程、微血管疾病及BMI影响。
研究设计与样本
- REWIND试验事后分析,评估度拉糖肽1.5 mg治疗患者基线至72个月治疗期间HbA1c变化。
主要发现
- 72个月治疗期间度拉糖肽组HbA1c较安慰剂组显著降低,最小二乘均值差=-0.61%(P<0.001)。
- HbA1c降低不受糖尿病病程、既往微血管疾病及BMI影响,交互作用P均>0.07。
- 各时间点均可见显著降低,且独立于上述基线特征。
- 0-12个月度拉糖肽组HbA1c下降速率高于安慰剂组,校正前后均如此。
- 12-72个月度拉糖肽组HbA1c上升速率高于安慰剂组,校正糖尿病病程、既往微血管疾病及BMI后无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. RESEARCH DESIGN AND METHODS: Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI. Slope analyses were used to assess the change in HbA1c during 0-12 months and 12-72 months of therapy. RESULTS: HbA1c was significantly reduced in patients treated with dulaglutide compared with placebo during 72 months of treatment (least-squares mean difference = -0.61%, P < 0.001), regardless of diabetes duration, prior microvascular disease, and BMI (all interaction P > 0.07). Significant reductions were apparent at all time points and were independent of these baseline characteristics. Slope analyses revealed that the dulaglutide group experienced a higher rate of HbA1c reduction compared with the placebo group from 0 to 12 months before and after adjustment. The dulaglutide group also experienced a higher rate of HbA1c increase from 12 to 72 months compared with the placebo group that became nonsignificant after adjustment for diabetes duration, prior microvascular disease, and BMI combined. Despite the greater rate of HbA1c increase in the dulaglutide group during this period, mean HbA1c values remained below baseline in the dulaglutide group and below mean HbA1c values in the placebo group. CONCLUSIONS: Dulaglutide 1.5-mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.
引用
- Kwan AYM, Gerstein HC, Basile J, et al. HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care. 2022. PMID: 35043140. doi:10.2337/dc21-1160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。